[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"relapsed-refractory-multiple-myeloma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:relapsed-refractory-multiple-myeloma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,74,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100623055","phase-3-a-study-comparing-azd0120-a-dual-targeted-car-t-against-b-cell-maturation-antigen-bcma-and-cd19-versus-standard-regimens-in-participants-with-relapsed-refractory-multiple-myeloma-durga-4-100623055",false,"NCT07391657","A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)","A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CART) Therapy Directed Against BCMA and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma.","DURGA-4","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Documented diagnosis of multiple myeloma according to the IMWG diagnostic criteria\n* Documented evidence of measurable disease:\n\n  1. Serum M-protein level ≥ 1 g\u002FdL\n  2. Urine M-protein level ≥ 200 mg\u002F24h\n  3. Serum immunoglobulin free light chain ≥ 10 mg\u002FdL (100 mg\u002FL) and abnormal serum immunoglobulin kappa lambda free light chain ratio\n* Documented evidence of PD by IMWG 2016 criteria based on investigator's determination during or after the most recent line of therapy. Participants with only 1 prior line of therapy must have progressed within 47 months of a stem cell transplant, or if not transplanted, then within 42 months of starting initial therapy\n* Received 1 to 3 lines of prior therapy including an IMiD and either a PI or a CD38 antibody. Participant must have undergone at least 2 complete cycles of treatment for each line of therapy, unless PD was the best response to the line of therapy\n* Eligible to receive at least one of the standard regimens (DKd, PVd, DPd, or Kd) as determined by the Investigator.\n* ECOG performance status score of 0 to 1\n* Adequate hematology and chemistry laboratory values:\n\n  1. Haemoglobin ≥ 8.0 g\u002FdL\n  2. Absolute neutrophil count ≥ 1 × 10\\^9\u002FL (1000 per mm3)\n  3. Platelet count ≥ 75 × 10\\^9\u002FL (75000 per mm3) in participants with \\\u003C 50% of bone marrow nucleated cells are plasma cells or ≥ 50 × 10\\^9\u002FL (50000 per mm3) in participants with ≥ 50% of bone marrow nucleated cells are plasma cells\n  4. Absolute lymphocyte count ≥ 300\u002FµL (0.3 × 109\u002FL)\n  5. Total bilirubin ≤ 1.5 × ULN in the absence of Gilbert's syndrome or ≤ 3 × ULN if the participant has Gilbert's syndrome. AST and ALT≤ 3.0 × ULN. CrCl by Cockcroft and Gault method ≥ 30 mL\u002Fminute\n\nExclusion Criteria:\n\n* Known active, or prior history of CNS involvement or exhibits clinical signs of meningeal involvement of MM.\n* Primary amyloidosis, active plasma cell leukaemia, Waldenstrom macroglobulinemia or Polyneuropathy Organomegaly Endocrinopathy M-protein and Skin (POEMS) syndrome.\n* Participants with primary refractory MM (failed to generate at least a minimal response to any prior therapy)\n* Significant neurological or psychiatric condition\n* Significant medical condition that places the participant at an unacceptable risk for treatment-related complications\n* Previously received any prior BCMA-targeted treatment\n* Previously received CAR-T or CAR-NK therapy directed at any target\n* Previously received T-cell engager therapy directed at any target\n* Previously received allogeneic stem cell transplantation at any time during prior therapy or received autologous stem cell transplantation within 12 weeks of randomization","ALL","18 Years",{"count":20,"type":21},508,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \\[daratumumab, carfilzomib, and dexamethasone\\], DPd \\[daratumumab, pomalidomide, and dexamethasone\\], PVd \\[pomalidomide, bortezomib and dexamethasone\\], or Kd \\[carfilzomib and dexamethasone\\]) in participants with RRMM.",[27],"Relapsed Refractory Multiple Myeloma",[29,30,31],"BCMA","CAR-T","CD19","RECRUITING","2026-06-29",{"date":35,"type":36},"2026-06-30","ACTUAL",{"date":38,"type":36},"2026-02-23",{"date":40,"type":21},"2030-07-29",{"name":42,"class":43},"AstraZeneca","INDUSTRY",138,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100580097","phase-2-elisa-in-relapsedrefractory-mm-100580097","NCT06832865","ELISA in Relapsed\u002FRefractory MM","A Phase 2 Study of Elranatamab in Combination With Isatuximab (ELISA) in Relapsed and Refractory Multiple Myeloma","Inclusion Criteria:\n\n* 1\\. This study will enroll patients with relapsed and refractory multiple myeloma who have had at least 2 prior lines of therapy including patients who have had previous treatment with both immunomodulatory drugs (IMiDs) and a proteasome inhibitor (PI). Prior therapy with anti-CD38 and anti-B cell maturation antigen (BCMA) target will be permitted except an anti-BCMA T cell engager. Patients cannot be refractory to an anti-CD38 antibody.\n* 2\\. Measurable disease of multiple myeloma as defined by at least one of the following:\n\n  * a. Serum monoclonal protein ≥ 0.5 g\u002FdL. Patients with IgD disease and lower amounts of monoclonal protein may be permitted to enroll with PI approval\n  * b. ≥ 200 mg of monoclonal protein in the urine on 24-hour electrophoresis\n  * c. Serum free light chain ≥ 100 mg\u002FL (10 mg\u002FdL) and abnormal serum free kappa to serum free lambda light chain (FLC) ratio (\\\u003C0.26 or \\>1.65)\n* 3\\. Age ≥18 years.\n\n  --a. The effects of elranatamab and isatuximab on the developing human fetus are unknown. For this reason and because anti-BCMA bispecific antibodies are known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and 4 months after the last dose of elranatamab and 5 months after the last dose of isatuximab. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n* 4\\. ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A).\n* 5\\. Participants must have adequate organ and marrow function as defined below:\n\n  * a. ANC ≥ 1000\u002FμL. G-CSF is not permitted within 7 days of screening.\n  * b. Platelet count ≥ 50,000\u002FµL. Platelet transfusion is not permitted within 7 days of screening.\n  * c. Hemoglobin ≥ 8 g\u002FdL. Red blood cell transfusions are permitted to meet eligibility criteria.\n  * d. Calculated creatinine clearance of ≥ 30 mL\u002Fmin by Cockcroft-Gault equation.\n  * e. Patient has adequate hepatic function, as evidenced by each of the following:\n\n    * Serum bilirubin values \\\u003C 2 mg\u002FdL; and\n    * Serum aspartate transaminase (ALT) and\u002For aspartate transaminase (AST) values\\\u003C 2.5 × the upper limit of normal (ULN) of the institutional laboratory reference range. Patients with elevated bilirubin due to Gilbert's syndrome may be permitted with PI approval (i.e., total bilirubin \\\u003C3 mg\u002FdL and normal direct bilirubin).\n* 6\\. Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* 7\\. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better.\n* 8\\. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* 1\\. Patients with active plasma cell leukemia, POEMS syndrome, or amyloidosis are excluded from this trial.\n* 2\\. Stem cell transplant within 12 weeks prior to enrollment, or active GVHD.\n* 3\\. Ongoing Grade ≥2 peripheral sensory or motor neuropathy.\n* 4\\. History of any grade peripheral sensory or motor neuropathy with prior BCMA directed therapy. History of GBS or GBS variants, or history of any Grade ≥3 peripheral motor polyneuropathy.\n* 5\\. Previous treatment with an anti-BCMA bispecific T cell engager.\n\n  --a. Prior treatment with anti-BCMA CAR-T and\u002For ADC therapy is permitted; however, the participant cannot be refractory to this therapy if it was administered as the last line prior to study enrollment.\n* 6\\. Participants who are receiving any investigational agents currently.\n* 7\\. Participants who have had myeloma therapy or investigational drug within 2 weeks prior to start of treatment or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier.\n* 8\\. Known or suspected hypersensitivity to the study drug or any components of the device (e.g. adhesive which contains acrylic).\n* 9\\. Impaired cardiovascular function or clinically significant cardiovascular diseases, defined as any of the following within 6 months prior to enrollment:\n\n  * a. Acute myocardial infarction, acute coronary syndromes (e.g., unstable angina, coronary artery bypass graft, coronary angioplasty or stenting, pericardial effusion);\n  * b. Clinically significant cardiac arrhythmias (e.g., uncontrolled atrial fibrillation or uncontrolled paroxysmal supraventricular tachycardia);\n  * c. Thromboembolic or cerebrovascular events (e.g., transient ischemic attack, cerebrovascular accident, deep vein thrombosis \\[unless associated with a central venous access complication\\] or pulmonary embolism);\n* 10\\. Participants with known active HBV, HCV, HIV, or any active, uncontrolled bacterial, fungal, or viral infection. Active infections must be resolved at least 14 days prior to enrollment. Per institutional protocol, HBV DNA testing by PCR is mandatory for subjects at risk for HBV reactivation.\n* 11\\. Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ and or other cancers treated with curative intent.\n* 12\\. Other surgical (including major surgery within past 14 days prior to enrollment) medical or psychiatric condition including recent (within the past year) or active suicidal ideation\u002Fbehavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.\n* 13\\. Live attenuated vaccine within 30 days of the first dose of study intervention.",{"count":53,"type":21},30,[55],"PHASE2","This is an open-label phase 2 study of elranatamab in combination with isatuximab administered subcutaneously in patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior lines of therapy and who have had previous treatment with both immunomodulatory drugs (IMiDs) and a proteasome inhibitor (PI). The subcutaneous injection method of isatuximab administration, including the device used to administer isatuximab, is investigational.",[58,27],"Relapsed Refractory Multiple Myeloma (RRMM)",[60,61,62],"Prior lines of therapy","relapsed and refractory multiple myeloma","RRMM","2026-03-11",{"date":65,"type":36},"2026-03-12",{"date":67,"type":36},"2025-08-14",{"date":69,"type":21},"2028-12-01",{"name":71,"class":72},"Massachusetts General Hospital","OTHER",3,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100576929","early-phase-1-a-study-of-eso-t01-in-treating-relapsed-refractory-multiple-myeloma-100576929","NCT06791681","A Study of ESO-T01 in Treating Relapsed\u002F Refractory Multiple Myeloma","Clinical Study for Evaluating ESO-T01 Injection's Safety and Efficacy in Treating Relapsed\u002Frefractory Multiple Myeloma","Inclusion Criteria:\n\n1. Age ≥ 18 years；\n2. Diagnosis of multiple myeloma (MM) confirmed according to the IMWG diagnostic criteria, with BCMA expression on MM cells determined by flow cytometry or immunohistochemistry;\n3. Previously treated with at least 2 lines of anti-MM therapy, with at least 1 complete treatment cycle for each line, and disease progression within 12 months after the most recent anti-myeloma treatment, or being refractory to both immunomodulatory drugs and proteasome inhibitors, along with disease progression within 2 months after the most recent anti-myeloma treatment (according to the IMWG diagnostic criteria);\n4. Disease must be measurable at screening, meeting at least one of the following criteria:Serum M-protein level ≥ 0.5 g\u002FdL; Urinary M-protein level ≥ 200 mg\u002F24h; Serum involved free light chain ≥ 10 mg\u002FdL and an abnormal serum free light chain κ\u002Fλ ratio;\n5. ECOG score 0-2, with an expected survival time ≥ 3 months;\n6. Bone marrow function at screening (or within 2 months prior to screening) meets the following criteria: a.Hemoglobin ≥ 6 g\u002FdL (no red blood cell transfusion within 1 week before screening), recombinant human erythropoietin is allowed; for patients who meet the ≥6 g\u002FdL criterion at screening, red blood cell transfusion is allowed to maintain hemoglobin ≥ 6 g\u002FdL; b.Absolute neutrophil count (ANC) ≥ 600\u002FμL (no use of granulocyte colony-stimulating factor (G-CSF) within 1 week or pegylated G-CSF within 2 weeks prior to screening); c. Platelet count ≥ 50,000\u002FμL; d. Lymphocyte count ≥ 500\u002FμL; e. Absolute CD3-positive T cell count ≥ 150\u002FμL;\n7. Renal function at screening (or within 2 months prior to screening) should be normal, with a creatinine clearance ≥ 45 mL\u002Fmin;\n8. Liver function at screening (or within 2 months prior to screening) must meet the following criteria: a. Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 3.0 × the upper limit of normal (ULN); b. Total bilirubin (TBIL) and alkaline phosphatase (AKP or ALP) ≤ 2.0 × ULN (except for congenital hyperbilirubinemia, such as Gilbert's syndrome, where direct bilirubin can be ≤ 1.5 × ULN); c. Albumin ≥ 3 g\u002FdL;\n9. Cardiac function at screening (or within 2 months prior to screening) must meet the following criteria: a. Left ventricular ejection fraction ≥ 40% (measured by echocardiogram or MUGA scan); b. No clinically significant pericardial effusion detected; c. No clinically significant ECG abnormalities detected;\n10. Pulmonary function at screening (or within 2 months prior to screening) must meet the following criteria: Oxygen saturation ≥ 90%;No clinically significant pleural effusion detected;\n11. For women of childbearing potential, a negative pregnancy test must be obtained at screening and prior to drug infusion, and they must not be breastfeeding;\n12. Male and female subjects of childbearing potential must agree to use effective contraception from the time of informed consent until 1 year after the study drug administration;\n13. Male and female subjects of childbearing potential must agree not to donate sperm or eggs (oocytes) or other reproductive cells from the time of informed consent until 1 year after the study drug administration;\n14. The participant or their legally authorized representative must provide written informed consent (ICF), indicating their understanding of the purpose and procedures of the study and their willingness to participate.\n\nExclusion Criteria:\n\n1. Previous anticancer treatment (as determined by the investigator): a. Received targeted therapy, epigenetic therapy, other investigational drugs, or treatment using invasive investigational medical devices within 5 half-lives; b. Received immune\u002Fnon-immune-directed systemic therapy within 1 week; Received cytotoxic therapy within 1 week; c. Received proteasome inhibitors or immunomodulatory agent therapy within 2 weeks; d. Received radiotherapy within 4 weeks (if the radiation field covered ≤5% of bone marrow reserve, the subject is eligible regardless of the date of radiotherapy completion);\n2. Received allogeneic HSCT within 6 months prior to infusion, or autologous HSCT within 3 months prior to infusion;\n3. Other malignancies prior to screening (except the following): Malignancies treated with curative intent and no evidence of active disease ≥2 years before enrollment; Adequately treated non-melanoma skin cancer with no evidence of disease;\n4. Previously treated with any viral therapy using VSVG pseudotype virus;\n5. Serious uncontrolled infections during screening: Bacterial, viral, fungal, etc. infections;\n6. Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with elevated peripheral blood HBV DNA levels within 6 months prior to infusion; Positive for hepatitis C antibody (HCV Ab) with elevated peripheral blood HCV RNA levels; Positive for HIV antibody; Positive for syphilis;\n7. Symptomatic heart failure or significant arrhythmias: NYHA Class III or IV congestive heart failure; Myocardial infarction or coronary artery bypass grafting (CABG) or coronary stent implantation within ≤6 months prior to signing ICF; Clinically significant ventricular arrhythmias or unexplained syncope (except when caused by vasovagal or dehydration); Significant non-ischemic cardiomyopathy history;\n8. Other significant diseases: Primary immunodeficiency; Stroke or seizure within 6 months prior to screening; Obvious clinical evidence of dementia or altered mental status; History of Parkinson's disease or Parkinsonism;\n9. Surgery within 2 weeks prior to treatment or planned surgery within 2 weeks post-treatment, except for local anesthesia procedures;\n10. Use of live-attenuated vaccines within 1 month before treatment;\n11. Known severe allergic reaction to ESO-T01 or its formulation components;\n12. Known severe allergic reaction to Tocilizumab;\n13. Inability to establish venous access;\n14. Any other condition deemed by the investigator as unsuitable for participation in the study.",{"count":82,"type":21},24,[84],"EARLY_PHASE1","This is a single center, single arm, open-label, dose-escalation clinical study to observe the safety, tolerability, preliminary efficacy, pharmacokinetics, pharmacodynamics of ESO-T01 injection for treating patients with relapsed\u002Frefractory multiple myeloma.",[87],"Relapsed\u002F Refractory Multiple Myeloma",[89,90,91],"ESO-T01","Multiple Myeloma","in vivo","2025-02-07",{"date":94,"type":36},"2025-02-11",{"date":96,"type":36},"2025-01-27",{"date":98,"type":21},"2027-11-30",{"name":100,"class":72},"Chunrui Li",1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":101},"100576324","a-novel-car-t-combined-expression-of-il-15-in-the-treatment-of-malignant-hematological-tumors-100576324","NCT06783816","A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors","A Multicenter, Single Arm, Open Label Clinical Study on the Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors","Inclusion Criteria:\n\n* I (or the authorized representative\u002Flegal guardian) agree and have signed an informed consent form, and am willing and capable of following the planned visits, research treatments, laboratory tests, and other research procedures;\n* Histopathological or flow cytometric diagnosis of CD19 and\u002For CD22, BCMA-positive hematological malignancies;\n\n  -≥15 years old, ≤80 years old;\n* If you meet one of the following three conditions, you can be included in the group:-Patients with recurrent or refractory hematologic malignancies treated with one standard chemotherapy regimen and one salvage regimen;-Minimal residual lesions persist after treatment with one standard chemotherapy regimen and one salvage regimen;-Patients with recurrence after hematopoietic stem cell transplantation;\n* Estimated survival ≥12 weeks;\n* Good heart, liver and kidney function:\n* Serum creatinine ≤ 1.5 mg\u002FdL (1mg\u002Fdl=88.4umol\u002FL); Serum ALT\u002FAST ≤ 2.5 ULN; Total bilirubin ≤ 1.5 mg\u002Fdl (1mg\u002Fdl=17.1umol\u002FL):\n* Cardiac ejection fraction ≥50%, cardiac ultrasound showed centropericardial effusion:\n* Eastern Oncology Collaborative Group Activity Status Score (ECOG)0-3;\n* Able to understand and voluntarily sign informed consent; If the subject is a child, the guardian will sign the informed consent.\n\nIf the answer to any of the above is \\"no\\", the subject will not be allowed to participate in this study.\n\nExclusion Criteria:\n\n* Have a New York Heart Association (NYHA) classification \\> Class III heart failure or myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically prominent heart disease within one year prior to signing the consent form, or have a QTC interval \\>480ms at the time of screening (QTC interval is calculated using the Fridericia formula);\n* Have active GVHD, or need immunosuppressants;\n* Other malignancies were present within 5 years prior to screening, except for adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, and breast ductal carcinoma in situ after radical resection of local prostate cancer;\n* The presence of an active or uncontrolled infection requiring systemic treatment (except for mild genitourinary and upper respiratory tract infections) in the 7 days prior to screening;\n* If HBSAg or HbCAb positive peripheral blood hepatitis B virus (HBV)DNA is higher than the lower limit of detection, it should be excluded. If hepatitis C virus (HCV) antibody positive, peripheral blood HCVRNA positive should be excluded; (HIV) antibody-positive; -Cytomegalovirus (CMV)DNA test positive for human immunodeficiency virus; Those who test positive for Treponema pallidum specific antibody (TPPA) should be excluded;\n* Participating in another clinical trial within 4 weeks prior to the signing of the informed consent, or the signing date of the informed consent is still within 5 half-lives of the drug (whichever is longer) since the last drug used in the last clinical trial;\n* A history of severe allergy to biological products;\n* Systemic diseases that are considered unstable by the investigator: including but not -limited to severe liver, kidney, or metabolic diseases requiring medical treatment;\n* Pregnant or lactating women, and female subjects who plan pregnancy within 2 years after cell transfusion or male subjects whose partner plans pregnancy within 2 years after cell transfusion;\n* Conditions that the investigator believes may increase the risk to the subject or interfere with the test results.",{"count":110,"type":21},45,[112],"NA","The is a multicenter, single arm, open label clinical study on the novel CAR-T combined expression of IL-15 in the treatment of malignant hematological tumors.Plan to recruit 45 subjects with malignant hematological tumors.",[115,116,27],"Acute Lymphocytic Leukemia","Lymphoma,Non-Hodgkin",[30,118,119],"IL-15","malignant hematological tumors","2025-01-15",{"date":122,"type":36},"2025-01-20",{"date":124,"type":36},"2023-12-01",{"date":126,"type":21},"2028-06-01",{"name":128,"class":72},"Shanxi Bethune Hospital"]